BioSphere Medical to Present at Roth Capital Partners 19th Annual OC Conference.ROCKLAND, Mass. -- BioSphere Medical, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BSMD), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids Uterine Fibroids Definition Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer. , hypervascularized tumors and vascular malformations, announced today that Richard Faleschini, president and chief executive officer, is scheduled to present at the Roth Capital Partners Roth Capital Partners, LLC, is a full service Investment Banking firm, specializing in the small and micro cap markets. Roth’s focus, according to its official website, "has been, is, and will continue to be providing the full spectrum of investment banking services, 19th Annual OC Conference on Tuesday, February 20, 2007 at 9:30 am Pacific Time / 12:30 pm Eastern Time. The Conference is being held at The Ritz Carlton in Laguna Niguel, California Laguna Niguel is a city located in southern Orange County, California. The name "Laguna Niguel" is derived from the Spanish word "Laguna" which means lagoon and the word "Nigueli" which was the name of a Juaneno Indian village once located on Aliso Creek. . The presentation will also be broadcast live over the Internet via the "Investors" page of the BioSphere Medical website at www.biospheremed.com or at http://www.wsw.com/webcast/roth9/bsmd/. To listen to the live event, go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available at the Company's website for 90 days following the presentation. About BioSphere Medical, Inc. BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, has pioneered and is commercializing minimally invasive diagnostic and therapeutic products based on its proprietary bioengineered microsphere Not to be confused with Glass microphere. This article largely refers to micropheres or protein protocells as small spherical units postulated by some scientists as a key stage in the origin of life. technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties, which the Company believes have the potential for use in a variety of medical applications. BioSphere's principal focus is the application of its Embosphere[R] Microspheres product for the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization Uterine Fibroid Embolization Definition Uterine fibroids are growths in the muscular tissue of the womb (uterus). Uterine fibroid embolization is non-surgical removal of the growths through the use of a tubular device called a catheter. , or UFE UFE Uterine Fibroid Embolization UFE United for a Fair Economy UFE Ufficio Federale dell'Energia UFE Uniform Final Examination UFE Urban Challenge Final Event (DARPA) UFE Unidentified Flags and Ensigns UFE Unrestricted Free Agent . The Company's products have continued to gain acceptance in this emerging procedure as well as in a number of other new and established medical treatments. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere's Quarterly Report on Form 10-Q for the quarter ended September 30, 2006, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion